The setting up of the Mauritius Institute of Biotechnology Ltd (“MIBL”) with a seed capital of around USD 25 million was announced by the Government of Mauritius in the 2021-2022 budget speech.
The mandate of the MIBL was extended during the 2022-2023 budget speech to include more segments beyond vaccine manufacturing as mentioned below.
In order to fast track the development of the pharmaceutical industry in Mauritius, an Inter-Ministerial Committee has been set up. A Technical Committee under the chairmanship of the Financial Secretary comprising of relevant stakeholders has identified short-, medium- and long-term priorities which relate to the below but are not limited to:
- Cultivation and production of nutraceutical products;
- Setting up of Clinical Research Organisations for performing clinical trials;
- Setting up of Centres for performing pre-clinical trials on animals;
- Regional Central Labs for servicing regional clinical research organisations;
- Setting up of Research and Development Centres for pharmaceutical development and testing;
- Manufacturing of Active Pharmaceutical Ingredients (APIs);
- Manufacturing of medical devices;
- Setting up of back-office facilities for distribution and/or minor manufacturing and packaging of pharmaceutical products for the region;
- Setting up of manufacturing facilities for therapeutic products against prevalent local and regional diseases such as diabetes, measles, cholera, cardiovascular deficiencies, among others;
- Setting of vaccine production facilities;
- Setting up of genomic testing facilities;
- Setting up of bottling and packaging facilities for pharmaceutical products.
For more information, we invite you to contact the Business Development Team by email at bd@juristax.com or call them on + 230 465 55 26.